Sumavel Dosepro is a drug owned by Endo Operations Ltd. It is protected by 16 US drug patents filed from 2013 to 2014. Out of these, 4 drug patents are active and 12 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 22, 2026. Details of Sumavel Dosepro's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sumavel Dosepro's patents.

Latest Legal Activities on Sumavel Dosepro's Patents

Given below is the list of recent legal activities going on the following patents of Sumavel Dosepro.

Activity	Date	Patent Number
Critical Events This Week
Expire Patent Critical	30 Aug, 2021	US8491524
Maintenance Fee Reminder Mailed Critical	15 Mar, 2021	US8491524
Expire Patent Critical	08 Feb, 2021	US8343130
Expire Patent Critical	23 Nov, 2020	US8287489
Expire Patent Critical	26 Oct, 2020	US8267903
Expire Patent Critical	21 Sep, 2020	US8241244
Expire Patent Critical	21 Sep, 2020	US8241243
Maintenance Fee Reminder Mailed Critical	24 Aug, 2020	US8343130
Maintenance Fee Reminder Mailed Critical	08 Jun, 2020	US8287489
Maintenance Fee Reminder Mailed Critical	11 May, 2020	US8267903

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

US patents provide insights into the exclusivity only within the United States, but Sumavel Dosepro is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sumavel Dosepro's family patents as well as insights into ongoing legal events on those patents.

Sumavel Dosepro's Family Patents

Sumavel Dosepro has patent protection in a total of 9 countries. It's US patent count contributes only to 44.7% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Sumavel Dosepro.

Full family tree

Generic Launch

About Sumavel Dosepro

Sumavel Dosepro is a drug owned by Endo Operations Ltd. Sumavel Dosepro uses Sumatriptan Succinate as an active ingredient. Sumavel Dosepro was launched by Endo Operations in 2013.